Stage III NSCLC RWE in Chinese Patients

AstraZeneca

Status: Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Study type: Observational

Funder types: Industry

Identifiers

NCT04023812

D4194R00009

Details and patient eligibility

About

The objectives of this study are to assess molecular testing, treatment patterns and associated clinical outcomes in Chinese patients with treatment-naïve stage III non-small cell lung cancer (NSCLC) in real world setting. This study is a prospective, non-interventional study. It is descriptive in nature and does not attempt to test any specific a priori hypotheses.

Enrollment: 500 patients

Sex: All

Ages: 18 to 130 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female aged 18 years or older.
• Provision of informed consent prior to any study specific procedures.
• Histologically or cytologically confirmed locally advanced, stage III NSCLC (according to version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology; IASLC Staging Manual in Thoracic Oncology).

Exclusion criteria

• Enrolment in studies that prohibit any participation in this observational study.

  • Patients may be concurrently enrolled in unblinded clinical trials, but not blinded clinical trials in which the treatment being administered is unknown.

• Prior surgery, radiotherapy or systemic therapy for NSCLC, including chemotherapy, targeted therapy, anti-angiogenesis, etc.

Trial design

500 participants in 2 patient groups

Cohort 1

Description:

Cohort 1, including patients without surgical resection, will be defined as unresectable stage III NSCLC

Cohort 2

Description:

Cohort 2,including patients with surgical resection, will be defined as resectable stage III NSCLC